116 related articles for article (PubMed ID: 7536073)
41. Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone.
Musto P; Sanpaolo G; D'Arena G; Scalzulli PR; Matera R; Falcone A; Bodenizza C; Perla G; Carotenuto M
Haematologica; 2001 Jan; 86(1):44-51. PubMed ID: 11146570
[TBL] [Abstract][Full Text] [Related]
42. Simultaneous administration of TPO and G-CSF after cytoreductive treatment of rhesus monkeys prevents thrombocytopenia, accelerates platelet and red cell reconstitution, alleviates neutropenia, and promotes the recovery of immature bone marrow cells.
Neelis KJ; Dubbelman YD; Qingliang L; Thomas GR; Eaton DL; Wagemaker G
Exp Hematol; 1997 Sep; 25(10):1084-93. PubMed ID: 9293906
[TBL] [Abstract][Full Text] [Related]
43. Use of peripheral blood stem cells for autologous transplantation in acute myeloid leukemia patients allows faster engraftment and equivalent disease-free survival compared with bone marrow cells.
Visani G; Lemoli R; Tosi P; Martinelli G; Testoni N; Ricci P; Motta M; Gherlinzoni F; Leopardi G; Pastano R; Rizzi S; Piccaluga P; Isidori A; Tura S
Bone Marrow Transplant; 1999 Sep; 24(5):467-72. PubMed ID: 10482929
[TBL] [Abstract][Full Text] [Related]
44. Alterations in L-selectin expression and elastase activity in neutrophils from patients receiving granulocyte colony-stimulating factor alone or in conjunction with high-dose chemotherapy with autologous bone marrow transplantation.
Rao KM; Currie MS; Cohen HJ; Peters WP
Lymphokine Cytokine Res; 1994 Dec; 13(6):383-90. PubMed ID: 7535570
[TBL] [Abstract][Full Text] [Related]
45. T cell-depleted granulocyte colony-stimulating factor (G-CSF) modified allogenic bone marrow transplantation for hematological malignancy improves graft CD34+ cell content but is associated with delayed pancytopenia.
Mavroudis DA; Read EJ; Molldrem J; Raptis A; Plante M; Carter CS; Phang S; Dunbar CE; Barrett AJ
Bone Marrow Transplant; 1998 Mar; 21(5):431-40. PubMed ID: 9535034
[TBL] [Abstract][Full Text] [Related]
46. Cytokine-primed bone marrow stem cells vs. peripheral blood stem cells for autologous transplantation: a randomized comparison of GM-CSF vs. G-CSF.
Weisdorf D; Miller J; Verfaillie C; Burns L; Wagner J; Blazar B; Davies S; Miller W; Hannan P; Steinbuch M; Ramsay N; McGlave P
Biol Blood Marrow Transplant; 1997 Oct; 3(4):217-23. PubMed ID: 9360784
[TBL] [Abstract][Full Text] [Related]
47. Delaying treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for hematological malignancies: a prospective randomized trial.
Ciernik IF; Schanz U; Gmür J
Bone Marrow Transplant; 1999 Jul; 24(2):147-51. PubMed ID: 10455342
[TBL] [Abstract][Full Text] [Related]
48. Late G-CSF after allogeneic bone marrow or peripheral blood stem cell transplantation: a prospective controlled trial.
Himmelmann B; Himmelmann A; Furrer K; Halter J; Schanz U
Bone Marrow Transplant; 2002 Oct; 30(8):491-6. PubMed ID: 12379887
[TBL] [Abstract][Full Text] [Related]
49. Very large amounts of peripheral blood progenitor cells eliminate severe thrombocytopenia after high-dose melphalan in advanced breast cancer patients.
Benedetti G; Patoia L; Giglietti A; Alessio M; Pelicci P; Grignani F
Bone Marrow Transplant; 1999 Nov; 24(9):971-9. PubMed ID: 10556956
[TBL] [Abstract][Full Text] [Related]
50. Optimal timing of G-CSF administration after CD34+ immunoselected peripheral blood progenitor cell transplantation.
Piccirillo N; Sica S; Laurenti L; Chiusolo P; La Barbera EO; Sorà F; Leone G
Bone Marrow Transplant; 1999 Jun; 23(12):1245-50. PubMed ID: 10414910
[TBL] [Abstract][Full Text] [Related]
51. A phase I trial of recombinant human interleukin-1 beta (OCT-43) following high-dose chemotherapy and autologous bone marrow transplantation.
Elkordy M; Crump M; Vredenburgh JJ; Petros WP; Hussein A; Rubin P; Ross M; Gilbert C; Modlin C; Meisenberg B; Coniglio D; Rabinowitz J; Laughlin M; Kurtzberg J; Peters WP
Bone Marrow Transplant; 1997 Feb; 19(4):315-22. PubMed ID: 9051240
[TBL] [Abstract][Full Text] [Related]
52. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
Bernstein SH; Christiansen NP; Fay JP; Brown R; Herzig R; Frankel S; Blumenson L; Herzig GP
Exp Hematol; 1996 Oct; 24(12):1363-8. PubMed ID: 8913281
[TBL] [Abstract][Full Text] [Related]
53. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
54. Serum erythropoietin levels and blood component therapy after autologous bone marrow transplantation: implications for erythropoietin therapy in this setting.
Lazarus HM; Goodnough LT; Goldwasser E; Long G; Arnold JL; Strohl KP
Bone Marrow Transplant; 1992 Jul; 10(1):71-5. PubMed ID: 1515882
[TBL] [Abstract][Full Text] [Related]
55. Clinical and laboratory experience in marrow harvesting in children for autologous bone marrow transplantation.
Cairo MS; VandeVen C; Toy C; Sender L
Bone Marrow Transplant; 1989 May; 4(3):305-8. PubMed ID: 2659115
[TBL] [Abstract][Full Text] [Related]
56. Trilineage recovery by combination therapy with recombinant human granulocyte colony-stimulating factor and erythropoietin in patients with aplastic anemia and refractory anemia.
Bessho M; Jinnai I; Hirashima K; Saito M; Murohashi I; Ino H; Tsuji M; Fukuda M; Maruyama M; Kusumoto S
Stem Cells; 1994 Nov; 12(6):604-15. PubMed ID: 7533579
[TBL] [Abstract][Full Text] [Related]
57. Accelerated erythroid repopulation with no stem-cell competition effect in children treated with recombinant human erythropoietin after allogeneic bone marrow transplantation.
Locatelli F; Zecca M; Beguin Y; Giorgiani G; Ponchio L; De Stefano P; Cazzola M
Br J Haematol; 1993 Aug; 84(4):752-4. PubMed ID: 8217839
[TBL] [Abstract][Full Text] [Related]
58. Recombinant human granulocyte colony-stimulating factor in allogeneic bone marrow transplantation.
Masaoka T; Takaku F; Kato S; Moriyama Y; Kodera Y; Kanamaru A; Shimosaka A; Shibata H; Nakamura H
Exp Hematol; 1989 Nov; 17(10):1047-50. PubMed ID: 2478381
[No Abstract] [Full Text] [Related]
59. Haematological improvement by long-term administration of recombinant human granulocyte-colony stimulating factor and recombinant human erythropoietin in a patient with severe aplastic anaemia.
Nawata J; Toyoda Y; Nisihira H; Honda K; Kigasawa H; Nagao T
Eur J Pediatr; 1994 May; 153(5):325-7. PubMed ID: 7518392
[TBL] [Abstract][Full Text] [Related]
60. Serum erythropoietin levels in allogeneic, non T-depleted bone marrow transplantation, and the effects of rhEpo administration.
Bosi A; Vannucchi AM; Grossi A; Guidi S; Rafanelli D; Saccardi R; Ferrini PR
Bone Marrow Transplant; 1991; 7 Suppl 2():87. PubMed ID: 1878736
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
